Last reviewed · How we verify
Eplerenone (Night-time)
Eplerenone (Night-time) is a Selective aldosterone antagonist (mineralocorticoid receptor antagonist) Small molecule drug developed by Vanderbilt University Medical Center. It is currently FDA-approved for Heart failure with reduced ejection fraction, Hypertension, Post-myocardial infarction left ventricular dysfunction. Also known as: Inspra.
Eplerenone is a selective aldosterone antagonist that blocks mineralocorticoid receptors in the kidney and other tissues, reducing sodium retention and potassium excretion.
Eplerenone is a selective aldosterone antagonist that blocks mineralocorticoid receptors in the kidney and other tissues, reducing sodium retention and potassium excretion. Used for Heart failure with reduced ejection fraction, Hypertension, Post-myocardial infarction left ventricular dysfunction.
At a glance
| Generic name | Eplerenone (Night-time) |
|---|---|
| Also known as | Inspra |
| Sponsor | Vanderbilt University Medical Center |
| Drug class | Selective aldosterone antagonist (mineralocorticoid receptor antagonist) |
| Target | Mineralocorticoid receptor (MR) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Eplerenone selectively inhibits aldosterone binding to mineralocorticoid receptors, preventing aldosterone-mediated sodium reabsorption and potassium excretion in the collecting duct. This leads to increased sodium and water excretion, reduced blood volume and blood pressure, and potassium retention. The night-time dosing formulation is designed to align with circadian patterns of aldosterone secretion and blood pressure regulation.
Approved indications
- Heart failure with reduced ejection fraction
- Hypertension
- Post-myocardial infarction left ventricular dysfunction
Common side effects
- Hyperkalemia
- Dizziness
- Fatigue
- Abdominal pain
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eplerenone (Night-time) CI brief — competitive landscape report
- Eplerenone (Night-time) updates RSS · CI watch RSS
- Vanderbilt University Medical Center portfolio CI
Frequently asked questions about Eplerenone (Night-time)
What is Eplerenone (Night-time)?
How does Eplerenone (Night-time) work?
What is Eplerenone (Night-time) used for?
Who makes Eplerenone (Night-time)?
Is Eplerenone (Night-time) also known as anything else?
What drug class is Eplerenone (Night-time) in?
What development phase is Eplerenone (Night-time) in?
What are the side effects of Eplerenone (Night-time)?
What does Eplerenone (Night-time) target?
Related
- Drug class: All Selective aldosterone antagonist (mineralocorticoid receptor antagonist) drugs
- Target: All drugs targeting Mineralocorticoid receptor (MR)
- Manufacturer: Vanderbilt University Medical Center — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Heart failure with reduced ejection fraction
- Indication: Drugs for Hypertension
- Indication: Drugs for Post-myocardial infarction left ventricular dysfunction
- Also known as: Inspra
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing